



## Content Disclaimer / Disclosure (SLXN)

***TL;DR: This content includes promotional materials for the issuer. Nothing in this communication is intended to provide tax, legal, or investment advice and nothing in this communication should be construed as a recommendation to buy, sell or hold any investment or security or to engage in any investment strategy or transaction. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or impaired due to the speculative nature of the companies profiled. Please read the full detailed disclosure before which include pertinent details that are not included in this brief summary.***



This communication was produced by Metrix Media, an affiliate of arx advisory ltd., (together “metrix”). Metrix is an integrated investor relations, data, communications, capital markets, and strategic advisory firm.. The information contained on this may fall under the category of ‘Paid Advertising’ for purposes of Section 17(b) of the Securities Act of 1933, as amended (together with the rules and regulations there under, the “Securities Act”). “metrix” and its affiliates are compensated by respective clients for publicizing information relating to its client’s which are generally publicly traded companies. Many times, this information may directly or indirectly refer to the company's security(ies). For more information in terms of compensation received for services provided by metrix, see the pertinent advertising materials relating to the respective client included at the bottom of the disclosure. By accessing this Site and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy.

“metrix” and its affiliates are not a registered or licensed broker, dealer, broker-dealer, investment adviser nor investment manager, nor does “metrix” engage in any activities that

would require such registrations. “metrix” and its affiliates do not provide investment advice, endorsement, analysis or recommendations with respect to any securities, and its services to or statements about its clients should never be construed as any endorsement of or opinion about any security of any client. No information contained in this communication constitutes an offer to sell, a solicitation of an offer to buy, or a recommendation of any security or any other similar product or service regardless of whether such security, product, or service is referenced in this communication.

Our articles, reports/releases, videos, and more are a commercial service and are for general information purposes ONLY. We are engaged in the business of marketing and promoting companies for monetary compensation. We usually focus favorable angles because we are compensated to publish only favorable information. We are not objective or independent and have multiple conflicts of interest. The Profiled Issuers and parties hiring us have conflicts of interest.

The contributors may buy and sell securities before, during and after any particular article, report and publication. In no event shall “metrix” or affiliates be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or made available by “metrix”, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. As mentioned, nothing in this communication is intended to provide tax, legal, or investment advice and nothing in this communication should be construed as a recommendation to buy, sell or hold any investment or security or to engage in any investment strategy or transaction. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk.

We urge Investors to conduct their own in-depth investigation of the Profiled Issuers with the assistance of their legal, tax and investment advisers. It is possible that an investor's investment may be lost or impaired due to the speculative nature of the companies profiled. Never invest in any stock featured by “metrix” and its affiliates unless you can afford to lose your entire investment. An investor’s review of the Information should include but not be limited to the Profiled Issuer’s financial condition, operations, management, products or services, trends in the industry and risks that may be material to the profiled Issuer’s business and other information he and his advisers deem material to an investment decision. We encourage our readers to invest carefully and read the investor information available at the web sites of the U.S. Securities and Exchange Commission (SEC) at [www.sec.gov](http://www.sec.gov) and the Financial Industry Regulatory Authority (FINRA) at [www.finra.org](http://www.finra.org).

Silexion Therapeutics Corp (NASDAQ: SLXN) is a client of ours and has an agreement in place to pay us a monthly cash fee of twenty four thousand dollars for four months starting September 2024 out of which a total of thirty eight thousand dollars are deferred fees to be paid at a later date. Additionally, after these four months, Silexion has an agreement in place to pay us a monthly ongoing cash fee of sixteen thousand dollars. These fees are being paid for for strategic capital markets advisory, market positioning, market research, risk monitoring, data strategy and among other, investor awareness and investor relations advisory services. Investor awareness and investor relations services and programs are designed to help emerging companies communicate their investment characteristics. Our awareness and advisory services include multimedia marketing and other awareness services.

Penny Stock Disclaimer: Many of the securities we profile are considered penny stocks. Penny stocks inherently involve high risk and price volatility. You may lose your entire investment in any penny stock that you invest in. You should be acutely aware of the following information and risks inherent in any penny stock investment that you may make, including any issuer profiled on our websites or otherwise: (a) we receive monetary or securities compensation from persons that claim they are a non-affiliate shareholder or an issuer; however, we conduct no due diligence whatsoever to determine whether in fact they are a non-affiliate; (b) there is an inherent conflict of interest between our information dissemination services involving various issuers and our receipt of compensation from those same issuers; (c) we may buy and sell securities in the securities that we provide information dissemination services, which may cause significant volatility in the issuer's stock, price declines from our selling activities, permit us to make substantial profits while we are disseminating profiles or information about the issuer, yet may result in a diminished value to the stock for investors; (c) we conduct no due diligence on the content of our Publications; (d) Penny stocks are subject to the SEC's penny stock rules and subject broker-dealers to customer suitability rules and other requirements, which may lead to low volume in the securities and/or difficulties in selling the shares; (e) penny stocks are often thinly traded or have low trading volume, which may lead to difficulties in selling your securities and extreme price volatility; (f) many of the penny stocks we profile or provide information about are subject to intense competition, extreme regulatory oversight and inadequate financing to pursue their operational plan; (g) the issuer profiles and information we provide is wholly insufficient to formulate an investment decision and should not be used in any way as a basis for making an investment decision and, at the most, it should be used a starting point from which you conduct an in-depth investigation of the issuer from available public sources, such as [www.sec.gov](http://www.sec.gov), [www.otcm Markets.com](http://www.otcm Markets.com), [www.sec.gov](http://www.sec.gov), [yahoofinance.com](http://yahoofinance.com), [www.google.com](http://www.google.com) and other available public sources as well as consulting with your financial professional, investment adviser, registered representative with a registered securities broker-dealer; (h) we urge you to conduct an in-depth investigation of the issuer from the above or other available sources, especially because we only present positive information, which is an

insufficient basis to invest in any stock, yet alone a penny stock; accordingly, you should proceed with such investigation to determine, among other things, information pertaining to the issuer's financial condition, operations, business model, and risks involved in the issuer's business; (i) the issuers we profile may have negative signs on the otcmarkets.com website (i.e. Stop Sign, No Information, Limited Information, Caveat Emptor), which you should determine from entering the symbol of the stock profiled into the otcmarkets.com website; (j) you should determine whether the issuer we profile or provide information about is a development stage company, which is subject to the risks of a development stage company in a similar such business, including difficulties in obtaining financing for operations and future growth; (k) because we only present positive information regarding an issuer, ; you should conduct an in-depth investigation of any possible negative factors regarding such issuer; (l) our information is "as is" and your use of the information is at your own risk and such information may change at any time and it is not based upon any verification or due diligence of the statements made; (m) we state that profiled stocks are consistent with future economic trends; however, future economic trends or analysis has its own limitations, including: (i) due to the complexity of economic analysis as well as the individual financial and operational characteristics of an individual issuer, such economic trends or predictions may amount to nothing more than speculation; (ii) consumers, producers, investors, borrowers, lenders and government may react in unforeseen ways and be affected by behavioral biases; (iii) human and social factors may outweigh future economic trends and predictions that we state may or will occur; (iv) clear cut economic predictions have their limitations in that they do not account for the fundamental uncertainty in economic life, as well as ordinary life; (v) economic trends may be disrupted by sudden jumps, disruptions or other factors that are not accounted for in such economic trends analysis; in other words, past or present data predicting future economic trends may become irrelevant in light of fully new circumstances and situations in which uncertainty becomes reality rather than of predictive economic quality; (vi) if the trends involves a single result, it ignores all other scenarios that may be crucial to make a decision in the event of various contingencies; (n) the information we disseminate about issuers contain forward looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, projections as indicated by such words as "expects", "will", "anticipates", "estimates; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation into any such forward looking statements; (o) forward looking statements are limited to the time period in which they are made and we do not undertake to update forward looking statements that may change at any time; and (p) we make statements in our profiles that an issuer's stock price has increased over a certain period of time; however, these statements only reflects an arbitrary period of time, and is of little or no predictive or analytical

Our content may include speculative forward looking statements. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. the BioTech and Pharma industries are volatile and risky and readers are advised to seek out preffesional advice in the relevent feilds from licensed professionals.